Avanir sues Impax over planned Nuedexta generic, Bloomberg reports Avanir Pharmaceuticals (AVNR) is suing Impax Laboratories (IPXL) for allegedly infringing a new patent for the drug Nuedexta and planning to market a generic version of the drug before the patent expires in 2023, reported Bloomberg, citing a complaint filed in a federal court in Delaware. Reference Link
News For AVNR;IPXL From The Last 14 Days
Check below for free stories on AVNR;IPXL the last two weeks.
Impax sees FY14 adjusted gross margin as percent of revenue to be upper 50% Sees FY14 R&d expenses $82M-$88M; Sees FY14 generic R&D expenses $46M-$49M; Sees FY14 brand R&D expenses $36M-$39M; Sees FY14 patent litigation expenses $11M-$13M; Sees FY14 SG&A expenses $115M-$120M; Sees FY14 CapEx $40M-$45M; Sees FY14 Hayward facility remediation costs of $25M-$30M; Sees FY14 effective tax rate of 32%-34%.